Janux Therapeutics, Inc.

Informe acción NasdaqGM:JANX

Capitalización de mercado: US$2.8b

Salud financiera de hoja de balance de Janux Therapeutics

Salud financiera controles de criterios 6/6

Janux Therapeutics tiene un patrimonio de los accionistas total de $656.1M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $695.0M y $38.9M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$658.03m
PatrimonioUS$656.10m
Total pasivoUS$38.92m
Activos totalesUS$695.02m

Actualizaciones recientes sobre salud financiera

Recent updates

Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Oct 01
Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Janux Therapeutics: Buoyed By Buyout Speculation

Sep 01

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Jul 01
Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Apr 11

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Feb 27

Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Feb 24
Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Dec 29
Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Nov 04
Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

Jul 20
We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

May 23
A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Feb 09
Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Oct 19
We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M

Aug 09

We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

Jun 05
We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Feb 19
Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Nov 03
Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($666.3M) de JANX superan a sus pasivos a corto plazo ($17.2M).

Pasivo a largo plazo: Los activos a corto plazo de JANX ($666.3M) superan a sus pasivos a largo plazo ($21.7M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: JANX está libre de deudas.

Reducción de la deuda: JANX no tenía deudas hace 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: JANX tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: JANX dispone de suficiente cash runway para más de 3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 41.1% cada año


Descubre empresas con salud financiera